Using curcumin, a known p300 inhibitor, in vitro and in vivo, Antoinette et al. (58) found that inhibition of p300 activity can reduce Smad acetylation and TGF-β activity, and reduce cardiac hypertrophy, improve diastolic function, and reduce extracellular matrix production, but not affect blood sugar. This evidence concerns the gene EP300 and cardiac hypertrophy.